Payment overview · 2025
General Payments
$196.64
3 reported records · 3 companies
Healthcare provider profile · identity verified
Kimberly K Hanigar, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MCLOUD, OK · NPI 1609858331
Verified facts
What the public records show
CMS Open Payments records show Kimberly K Hanigar, M.D. received $196.64 in general payments during 2025 across 3 reported records.
Abbott Laboratories accounted for 81.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $159.69 | 81.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.69 | 10.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.26 | 8.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $196.64 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $159.69 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 329 | 108 |
| Lisinopril | Lisinopril | 290 | 95 |
| Gabapentin | Gabapentin | 222 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 216 | 69 |
| Losartan Potassium | Losartan Potassium | 215 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 205 | 78 |
| Omeprazole | Omeprazole | 200 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 64 |
| Furosemide | Furosemide | 170 | 65 |
| Metformin Hcl | Metformin Hcl | 153 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 119 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 38 |
| Montelukast Sodium | Montelukast Sodium | 113 | 39 |
| Pregabalin | Pregabalin | 112 | 28 |
| Celecoxib | Celecoxib | 106 | 34 |
| Eliquis | Apixaban | 106 | 27 |
| Alprazolam | Alprazolam | 105 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 27 |
| Simvastatin | Simvastatin | 94 | 27 |
| Jardiance | Empagliflozin | 91 | 31 |
| Lovastatin | Lovastatin | 91 | 32 |
| Carvedilol | Carvedilol | 87 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 31 |
| Glipizide Er | Glipizide | 81 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 30 |
| Trazodone Hcl | Trazodone Hcl | 79 | 31 |
| Ozempic | Semaglutide | 75 | 22 |
| Potassium Chloride | Potassium Chloride | 75 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 27 |
| Farxiga | Dapagliflozin Propanediol | 67 | 14 |
| Ibuprofen | Ibuprofen | 67 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 30 |
| Eszopiclone | Eszopiclone | 65 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 30 |
| Tramadol Hcl | Tramadol Hcl | 64 | 22 |
| Ezetimibe | Ezetimibe | 62 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 20 |
| Finasteride | Finasteride | 58 | 19 |
| Alendronate Sodium | Alendronate Sodium | 53 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 12 |
| Estradiol | Estradiol | 49 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 17 |
| Temazepam | Temazepam | 48 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 27 |
| Allopurinol | Allopurinol | 45 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 15 |
| Sertraline Hcl | Sertraline Hcl | 43 | 17 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | 18 |
| Januvia | Sitagliptin Phosphate | 36 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Meloxicam | Meloxicam | 35 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Nabumetone | Nabumetone | 35 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 33 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 23 |
| Clonidine Hcl | Clonidine Hcl | 32 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 14 |
| Ondansetron Odt | Ondansetron | 32 | 15 |
| Prednisone | Prednisone | 32 | 23 |
| Buspirone Hcl | Buspirone Hcl | 31 | 13 |
| Fenofibrate | Fenofibrate | 31 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 28 |
| Cimetidine | Cimetidine | 30 | 11 |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Spironolactone | Spironolactone | 29 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Nystatin | Nystatin | 27 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 23 |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 20 |
| Primidone | Primidone | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 16 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | 15 |
| Torsemide | Torsemide | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $196.64 · 3 records | Abbott Laboratories | FREESTYLE LIBRE 3, Kerendia, OTEZLA, REPATHA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error